Diarrhoea is the most common disease globally. Although typically being a self-limiting condition in western civilisations, it can be a killer in low- and middle-income countries, where it is a leading cause of death and high morbidity for children under five years of age. 

 

Under the coordination of the European Vaccine Initiative (EVI), and partners including Eveliqure Biotechnologies (Austria), icddr, b (Bangladesh), University of Gothenburg (Sweden), and PATH (United States), the SHIGETECVAX consortium is dedicated to advancing a radically new approach developed by Eveliqure Biotechnologies. This combination vaccine is designed to prevent infections with Shigella and enterotoxigenic Escherichia coli (ETEC), two bacteria that cause significant cases of diarrhoea and suffering globally.